PMID- 34329401
OWN - NLM
STAT- MEDLINE
DCOM- 20220330
LR  - 20220531
IS  - 1532-2092 (Electronic)
IS  - 1099-5129 (Print)
IS  - 1099-5129 (Linking)
VI  - 24
IP  - 2
DP  - 2022 Feb 2
TI  - Different circulating biomarkers in women and men with paroxysmal atrial 
      fibrillation: results from the AF-RISK and RACE V studies.
PG  - 193-201
LID - 10.1093/europace/euab179 [doi]
AB  - AIMS: The clinical risk profile of atrial fibrillation (AF) patients is different 
      in men and women. Our aim was to identify sex differences in blood biomarkers in 
      patients with paroxysmal AF. METHODS AND RESULTS: Sex differences in 92 blood 
      biomarkers were measured in 364 patients included in our discovery cohort, the 
      identification of a risk profile to guide atrial fibrillation therapy (AF-RISK) 
      study, assessed by multivariable logistic regression and enrichment pathway 
      analysis. Findings were subsequently confirmed in 213 patients included in our 
      validation cohort, the Reappraisal of Atrial Fibrillation: Interaction between 
      HyperCoagulability, Electrical remodelling, and Vascular Destabilisation in the 
      Progression of AF (RACE V) study. In the discovery cohort, mean age was 
      59 +/- 12 years, 41% were women. CHA2DS2-VASc-score was 1.6 +/- 1.4. A total of 46% 
      had hypertension, 10% diabetes, and 50% had heart failure, predominantly with 
      preserved ejection fraction (47%). In women, activated leucocyte cell adhesion 
      molecule (ALCAM) and fatty acid binding protein-4 (FABP-4) were higher. In men, 
      matrix metalloproteinase-3 (MMP-3), C-C motif chemokine-16 (CCL-16), and 
      myoglobin were higher. In the validation cohort, four out of five biomarkers 
      could be confirmed: levels of ALCAM (P = 1.73 x 10-4) and FABP-4 (P = 2.46 x 
      10-7) and adhesion biological pathways [false discovery rate (FDR) = 1.23 x 10-8] 
      were higher in women. In men, levels of MMP-3 (P = 4.31 x 10-8) and myoglobin 
      (P = 2.10 x 10-4) and markers for extracellular matrix degradation biological 
      pathways (FDR = 3.59 x 10-9) were higher. CONCLUSION: In women with paroxysmal 
      AF, inflammatory biomarkers were more often higher, while in men with paroxysmal 
      AF, biomarkers for vascular remodelling were higher. Our data support the 
      clinical notion that pathophysiological mechanisms in women and men with AF may 
      differ. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT01510210 for 
      AF-RISK; Clinicaltrials.gov NCT02726698 for RACE V.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the 
      European Society of Cardiology.
FAU - De With, Ruben R
AU  - De With RR
AD  - Department of Cardiology, University of Groningen, University Medical Centre 
      Groningen, Groningen, Hanzeplein 1, 9713 GZ, The Netherlands.
FAU - Artola Arita, Vicente
AU  - Artola Arita V
AUID- ORCID: 0000-0002-3043-1675
AD  - Department of Cardiology, University of Groningen, University Medical Centre 
      Groningen, Groningen, Hanzeplein 1, 9713 GZ, The Netherlands.
FAU - Nguyen, Bao-Oanh
AU  - Nguyen BO
AD  - Department of Cardiology, University of Groningen, University Medical Centre 
      Groningen, Groningen, Hanzeplein 1, 9713 GZ, The Netherlands.
FAU - Linz, Dominik
AU  - Linz D
AD  - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The 
      Netherlands.
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 
      Maastricht, The Netherlands.
AD  - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
AD  - Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide 
      Hospital, Adelaide, Australia.
AD  - Department of Biomedical Sciences, Faculty of Health and Medical Sciences, 
      University of Copenhagen, Copenhagen, Denmark.
FAU - Ten Cate, Hugo
AU  - Ten Cate H
AUID- ORCID: 0000-0001-7796-4463
AD  - Departments of Biochemistry, Thrombosis Expertise Center (TEC) Maastricht, 
      Maastricht, The Netherlands.
AD  - Internal Medicine, Cardiovascular Research Institute Maastricht (CARIM), 
      Maastricht University, Maastricht, The Netherlands.
AD  - Maastricht University Medical Center+, Maastricht, The Netherlands.
FAU - Spronk, Henri
AU  - Spronk H
AD  - Departments of Biochemistry, Thrombosis Expertise Center (TEC) Maastricht, 
      Maastricht, The Netherlands.
AD  - Internal Medicine, Cardiovascular Research Institute Maastricht (CARIM), 
      Maastricht University, Maastricht, The Netherlands.
AD  - Maastricht University Medical Center+, Maastricht, The Netherlands.
FAU - Schotten, Ulrich
AU  - Schotten U
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 
      Maastricht, The Netherlands.
AD  - Department of Cardiology, Radboud University Medical Centre, Nijmegen, The 
      Netherlands.
FAU - Jan van Zonneveld, Anton
AU  - Jan van Zonneveld A
AD  - Department of Internal Medicine (Nephrology), Einthoven Laboratory for Vascular 
      and Regenerative Medicine, Leiden University Medical Center, Leiden, The 
      Netherlands.
FAU - Erkuner, Omer
AU  - Erkuner O
AD  - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The 
      Netherlands.
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 
      Maastricht, The Netherlands.
FAU - Bayon, M Agustina
AU  - Bayon MA
AD  - Department of Cardiology, University of Groningen, University Medical Centre 
      Groningen, Groningen, Hanzeplein 1, 9713 GZ, The Netherlands.
FAU - Schmidt, Anders S
AU  - Schmidt AS
AD  - Department of Internal Medicine, Randers Regional Hospital, Randers, Denmark.
AD  - Centre for Emergency Medicine, Institute for Clinical Medicine, Aarhus 
      University, Aarhus, Denmark.
FAU - Luermans, Justin G L M
AU  - Luermans JGLM
AD  - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The 
      Netherlands.
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 
      Maastricht, The Netherlands.
FAU - Crijns, Harry J G M
AU  - Crijns HJGM
AUID- ORCID: 0000-0003-1073-5337
AD  - Department of Cardiology, Maastricht University Medical Centre+, Maastricht, The 
      Netherlands.
AD  - Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 
      Maastricht, The Netherlands.
FAU - Van Gelder, Isabelle C
AU  - Van Gelder IC
AD  - Department of Cardiology, University of Groningen, University Medical Centre 
      Groningen, Groningen, Hanzeplein 1, 9713 GZ, The Netherlands.
FAU - Rienstra, Michiel
AU  - Rienstra M
AUID- ORCID: 0000-0002-2581-070X
AD  - Department of Cardiology, University of Groningen, University Medical Centre 
      Groningen, Groningen, Hanzeplein 1, 9713 GZ, The Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT01510210
SI  - ClinicalTrials.gov/NCT02726698
PT  - Clinical Study
PT  - Journal Article
PL  - England
TA  - Europace
JT  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal 
      of the working groups on cardiac pacing, arrhythmias, and cardiac cellular 
      electrophysiology of the European Society of Cardiology
JID - 100883649
RN  - 0 (Biomarkers)
SB  - IM
MH  - Aged
MH  - *Atrial Fibrillation
MH  - *Atrial Remodeling
MH  - Biomarkers
MH  - Cohort Studies
MH  - Female
MH  - *Heart Failure
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Assessment
MH  - Risk Factors
PMC - PMC8824515
OTO - NOTNLM
OT  - *Atrial fibrillation
OT  - *Blood biomarkers
OT  - *Inflammation
OT  - *Sex differences
OT  - *Vascular disease
EDAT- 2021/07/31 06:00
MHDA- 2022/03/31 06:00
PMCR- 2021/07/30
CRDT- 2021/07/30 17:25
PHST- 2020/10/09 00:00 [received]
PHST- 2021/06/29 00:00 [accepted]
PHST- 2021/07/31 06:00 [pubmed]
PHST- 2022/03/31 06:00 [medline]
PHST- 2021/07/30 17:25 [entrez]
PHST- 2021/07/30 00:00 [pmc-release]
AID - 6331356 [pii]
AID - euab179 [pii]
AID - 10.1093/europace/euab179 [doi]
PST - ppublish
SO  - Europace. 2022 Feb 2;24(2):193-201. doi: 10.1093/europace/euab179.